Syphilis rates have been rising in pregnant women and babies for about a decade.
The report is in response to a continent-wide surge in STIs since 2014.
Zoliflodacin and gepotidacin are the first new antibiotics approved for treating gonorrhea in decades.
Study findings show that a single oral dose of zoliflodacin is noninferior to the standard treatment regimen for uncomplicated gonorrhea.
Officials warn rising drug resistance could undo decades of progress in controlling HIV, hepatitis, and sexually transmitted infections.
Data from a new surveillance report show rising resistance to ceftriaxone and cefixime, the two antibiotics currently recommended for gonorrhea treatment.
High-level tetracycline resistance and reduced susceptibility to cefixime was found in gonorrhea bacteria from doxyPEP users.
Reported cases of chlamydia, gonorrhea, and syphilis declined for the third straight year in 2024, but cases of newborn syphilis were up by 2%.
The results of a randomized controlled trial show a single dose of benzathine penicillin G is noninferior to 3 doses for treating early syphilis.
The UK's National Health Service is offering the 4CMenB vaccine, which provides cross-protection against gonorrhea, to patients at the greatest risk of infection.
